___

• Ahola-Erkkila S, Carroll CJ, Peltola-Mjosund K, Tulkki V, Mattila I, Seppanen-Laakso T, Oresic M, Tyynismaa H, Suomalainen A (2010). Ketogenic diet slows down mitochondrial myopathy progression in mice. Hum Mol Genet 19: 1974–1984.
• Alavi MV, Fuhrmann N (2013). Dominant optic atrophy, OPA1, and mitochondrial quality control: understanding mitochondrial network dynamics. Mol Neurodegener 8: 32.
• Anderson S, Bankier AT, Barrell BG, de Bruijn MH, Coulson AR, Drouin J, Eperon IC, Nierlich DP, Roe BA, Sanger F et al. (1981). Sequence and organization of the human mitochondrial genome. Nature 290: 457–465.
• Andreux PA, Houtkooper RH, Auwerx J (2013). Pharmacological approaches to restore mitochondrial function. Nat Rev Drug Discov 12: 465–483.
• Andrews RM, Kubacka I, Chinnery PF, Lightowlers RN, Turnbull DM, Howell N (1999). Reanalysis and revision of the Cambridge reference sequence for human mitochondrial DNA. Nat Genet 23: 147.
• Bacman SR, Williams SL, Duan D, Moraes CT (2012). Manipulation of mtDNA heteroplasmy in all striated muscles of newborn mice by AAV9-mediated delivery of a mitochondria-targeted restriction endonuclease. Gene Ther 19: 1101–1106.
• Baracca A, Sgarbi G, Mattiazzi M, Casalena G, Pagnotta E, Valentino ML, Moggio M, Lenaz G, Carelli V, Solaini G (2007).
• Biochemical phenotypes associated with the mitochondrial ATP6 gene mutations at nt8993. Biochim Biophys Acta 1767: 913–919.
• Bender A, Krishnan KJ, Morris CM, Taylor GA, Reeve AK, Perry RH, Jaros E, Hersheson JS, Betts J, Klopstock T et al. (2006). High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat Genet 38: 515–517.
• Bernsen PL, Gabreels FJ, Ruitenbeek W, Hamburger HL (1993). Treatment of complex I deficiency with riboflavin. J Neurol Sci 118: 181–187.
• Betts J, Lightowlers RN, Turnbull DM (2004). Neuropathological aspects of mitochondrial DNA disease. Neurochem Res 29: 505–511.
• Blok RB, Gook DA, Thorburn DR, Dahl HH (1997). Skewed segregation of the mtDNA nt 8993 (T-->G) mutation in human oocytes. Am J Hum Genet 60: 1495–1501.
• Boch J, Scholze H, Schornack S, Landgraf A, Hahn S, Kay S, Lahaye T, Nickstadt A, Bonas U (2009). Breaking the code of DNA binding specificity of TAL-type III effectors. Science 326: 1509–1512.
• Bogenhagen DF, Clayton DA (2003a). Concluding remarks: the mitochondrial DNA replication bubble has not burst. Trends Biochem Sci 28: 404–405.
• Bogenhagen DF, Clayton DA (2003b). The mitochondrial DNA replication bubble has not burst. Trends Biochem Sci 28: 357– 360.
• Bonawitz ND, Chatenay-Lapointe M, Pan Y, Shadel GS (2007). Reduced TOR signaling extends chronological life span via increased respiration and upregulation of mitochondrial gene expression. Cell Metab 5: 265–277.
• Bonnefont JP, Bastin J, Laforet P, Aubey F, Mogenet A, Romano S, Ricquier D, Gobin-Limballe S, Vassault A, Behin A et al. (2010).
• Long-term follow-up of bezafibrate treatment in patients with the myopathic form of carnitine palmitoyltransferase 2 deficiency. Clin Pharmacol Ther 88: 101–108.
• Bornstein B, Area E, Flanigan KM, Ganesh J, Jayakar P, Swoboda KJ, Coku J, Naini A, Shanske S, Tanji K et al. (2008). Mitochondrial DNA depletion syndrome due to mutations in the RRM2B gene. Neuromuscul Disord 18: 453–459.
• Bouchet C, Steffann J, Corcos J, Monnot S, Paquis V, Rotig A, Lebon S, Levy P, Royer G, Giurgea I et al. (2006). Prenatal diagnosis of myopathy, encephalopathy, lactic acidosis, and stroke-like syndrome: contribution to understanding mitochondrial DNA segregation during human embryofetal development. J Med Genet 43: 788–792.
• Boveris A, Oshino N, Chance B (1972). The cellular production of hydrogen peroxide. Biochem J 128: 617–630.
• Brierley EJ, Johnson MA, Lightowlers RN, James OF, Turnbull DM (1998). Role of mitochondrial DNA mutations in human aging: implications for the central nervous system and muscle. Ann Neurol 43: 217–223.
• Brown WM, George M Jr, Wilson AC (1979). Rapid evolution of animal mitochondrial DNA. P Natl Acad Sci USA 76: 1967– 1971.
• Bugiani M, Lamantea E, Invernizzi F, Moroni I, Bizzi A, Zeviani M, Uziel G (2006). Effects of riboflavin in children with complex II deficiency. Brain Dev 28: 576–581.
• Cagin U, Enriquez JA (2015). The complex crosstalk between mitochondria and the nucleus: what goes in between? Int J Biochem Cell Biol 63: 10–15.
• Calvo SE, Compton AG, Hershman SG, Lim SC, Lieber DS, Tucker EJ, Laskowski A, Garone C, Liu S, Jaffe DB et al. (2012). Molecular diagnosis of infantile mitochondrial disease with targeted next-generation sequencing. Sci Transl Med 4: 118ra110.
• Carelli V, La Morgia C, Valentino ML, Rizzo G, Carbonelli M, De Negri AM, Sadun F, Carta A, Guerriero S, Simonelli F et al. (2011). Idebenone treatment in Leber’s hereditary optic neuropathy. Brain 134: e188.
• Carrodeguas JA, Theis K, Bogenhagen DF, Kisker C (2001). Crystal structure and deletion analysis show that the accessory subunit of mammalian DNA polymerase gamma, Pol gamma B, functions as a homodimer. Mol Cell 7: 43–54.
• Carroll CJ, Brilhante V, Suomalainen A (2014). Next-generation sequencing for mitochondrial disorders. Br J Pharmacol 171: 1837–1853.
• Chinnery PF, DiMauro S, Shanske S, Schon EA, Zeviani M, Mariotti C, Carrara F, Lombes A, Laforet P, Ogier H et al. (2004). Risk of developing a mitochondrial DNA deletion disorder. Lancet 364: 592–596.
• Chinnery PF, Taylor RW, Diekert K, Lill R, Turnbull DM, Lightowlers RN (1999). Peptide nucleic acid delivery to human mitochondria. Gene Ther 6: 1919–1928.
• Clayton DA (1982). Replication of animal mitochondrial DNA. Cell 28: 693–705.
• Copeland WC (2008). Inherited mitochondrial diseases of DNA replication. Annu Rev Med 59: 131–146.
• Corral-Debrinski M, Horton T, Lott MT, Shoffner JM, Beal MF, Wallace DC (1992a). Mitochondrial DNA deletions in human brain: regional variability and increase with advanced age. Nat Genet 2: 324–329.
• Corral-Debrinski M, Shoffner JM, Lott MT, Wallace DC (1992b). Association of mitochondrial DNA damage with aging and coronary atherosclerotic heart disease. Mutat Res 275: 169– 180.
• Cortopassi GA, Shibata D, Soong NW, Arnheim N (1992). A pattern of accumulation of a somatic deletion of mitochondrial DNA in aging human tissues. P Natl Acad Sci USA 89: 7370–7374.
• Cree LM, Patel SK, Pyle A, Lynn S, Turnbull DM, Chinnery PF, Walker M (2008a). Age-related decline in mitochondrial DNA copy number in isolated human pancreatic islets. Diabetologia 51: 1440–1443.
• Cree LM, Samuels DC, de Sousa Lopes SC, Rajasimha HK, Wonnapinij P, Mann JR, Dahl HH, Chinnery PF (2008b). A reduction of mitochondrial DNA molecules during embryogenesis explains the rapd segregation of genotypes. Nat Genet 40: 249–254.
• Danan C, Sternberg D, Van Steirteghem A, Cazeneuve C, Duquesnoy P, Besmond C, Goossens M, Lissens W, Amselem S (1999). Evaluation of parental mitochondrial inheritance in neonates born after intracytoplasmic sperm injection. Am J Hum Genet 65: 463–473.
• Danhauser K, Iuso A, Haack TB, Freisinger P, Brockmann K, Mayr JA, Meitinger T, Prokisch H (2011). Cellular rescue-assay aids verification of causative DNA-variants in mitochondrial complex I deficiency. Mol Genet Metab 103: 161–166.
• DiMauro S, Rustin P (2009). A critical approach to the therapy of mitochondrial respiratory chain and oxidative phosphorylation diseases. Biochim Biophys Acta 1792: 1159–1167.
• DiMauro S, Schon EA (2001). Mitochondrial DNA mutations in human disease. Am J Med Genet 106: 18–26.
• Dogan SA, Trifunovic A (2011). Modelling mitochondrial dysfunction in mice. Physiol Res 60 (Suppl 1): S61–70. Dragicevic N, Copes N, O’Neal-Moffitt G, Jin J, Buzzeo R, Mamcarz M, Tan J, Cao C, Olcese JM, Arendash GW et al. (2011).
• Melatonin treatment restores mitochondrial function in Alzheimer’s mice: a mitochondrial protective role of melatonin membrane receptor signaling. J Pineal Res 51: 75–86.
• Dunn DA, Cannon MV, Irwin MH, Pinkert CA (2012). Animal models of human mitochondrial DNA mutations. Biochim Biophys Acta 1820: 601–607.
• Ernster L, Dallner G (1995). Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta 1271: 195–204.
• Filosto M, Mancuso M, Vives-Bauza C, Vila MR, Shanske S, Hirano M, Andreu AL, DiMauro S (2003). Lack of paternal inheritance of muscle mitochondrial DNA in sporadic mitochondrial myopathies. Ann Neurol 54: 524–526.
• Frahm T, Mohamed SA, Bruse P, Gemund C, Oehmichen M, Meissner C (2005). Lack of age-related increase of mitochondrial DNA amount in brain, skeletal muscle and human heart. Mech Ageing Dev 126: 1192–1200.
• Furda AM, Marrangoni AM, Lokshin A, Van Houten B (2012). Oxidants and not alkylating agents induce rapid mtDNA loss and mitochondrial dysfunction. DNA Repair (Amst) 11: 684– 692.
• Galano A, Tan DX, Reiter RJ (2011). Melatonin as a natural ally against oxidative stress: a physicochemical examination. J Pineal Res 51: 1–16.
• Gammage PA, Rorbach J, Vincent AI, Rebar EJ, Minczuk M (2014). Mitochondrially targeted ZFNs for selective degradation of pathogenic mitochondrial genomes bearing large-scale deletions or point mutations. EMBO Mol Med 6: 458–466.
• Giles RE, Blanc H, Cann HM, Wallace DC (1980). Maternal inheritance of human mitochondrial DNA. P Natl Acad Sci USA 77: 6715–6719.
• Golubitzky A, Dan P, Weissman S, Link G, Wikstrom JD, Saada A (2011). Screening for active small molecules in mitochondrial complex I deficient patient’s fibroblasts, reveals AICAR as the most beneficial compound. PLoS One 6: e26883.
• Goto Y, Nonaka I, Horai S (1990). A mutation in the tRNA(Leu) (UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. Nature 348: 651–653.
• Grady JP, Campbell G, Ratnaike T, Blakely EL, Falkous G, Nesbitt V, Schaefer AM, McNally RJ, Gorman GS, Taylor RW et al. (2014). Disease progression in patients with single, large-scale mitochondrial DNA deletions. Brain 137: 323–334.
• Greaves LC, Barron MJ, Campbell-Shiel G, Kirkwood TB, Turnbull DM (2011). Differences in the accumulation of mitochondrial defects with age in mice and humans. Mech Ageing Dev 132: 588–591.
• Greaves LC, Reeve AK, Taylor RW, Turnbull DM (2012). Mitochondrial DNA and disease. J Pathol 226: 274–286.
• Hashimoto M, Bacman SR, Peralta S, Falk MJ, Chomyn A, Chan DC, Williams SL, Moraes CT (2015). MitoTALEN: A general approach to reduce mutant mtDNA loads and restore oxidative phosphorylation function in mitochondrial diseases. Mol Ther (in press).
• He L, Chinnery PF, Durham SE, Blakely EL, Wardell TM, Borthwick GM, Taylor RW, Turnbull DM (2002). Detection and quantification of mitochondrial DNA deletions in individual cells by real-time PCR. Nucleic Acids Res 30: e68.
• Hellebrekers DM, Wolfe R, Hendrickx AT, de Coo IF, de Die CE, Geraedts JP, Chinnery PF, Smeets HJ (2012). PGD and heteroplasmic mitochondrial DNA point mutations: a systematic review estimating the chance of healthy offspring. Hum Reprod Update 18: 341–349.
• Hensen F, Cansiz S, Gerhold JM, Spelbrink JN (2014). To be or not to be a nucleoid protein: a comparison of mass-spectrometry based approaches in the identification of potential mtDNAnucleoid associated proteins. Biochimie 100: 219–226.
• Hockemeyer D, Wang H, Kiani S, Lai CS, Gao Q, Cassady JP, Cost GJ, Zhang L, Santiago Y, Miller JC et al. (2011). Genetic engineering of human pluripotent cells using TALE nucleases. Nat Biotechnol 29: 731–734.
• Holt IJ, Harding AE, Morgan-Hughes JA (1988). Deletions of muscle mitochondrial DNA in patients with mitochondrial myopathies. Nature 331: 717–719.
• Holt IJ, Jacobs HT (2003). Response: the mitochondrial DNA replication bubble has not burst. Trends Biochem Sci 28: 355– 356.
• Holt IJ, Lorimer HE, Jacobs HT (2000). Coupled leading- and lagging-strand synthesis of mammalian mitochondrial DNA. Cell 100: 515–524.
• Holt IJ, Miller DH, Harding AE (1989). Genetic heterogeneity and mitochondrial DNA heteroplasmy in Leber’s hereditary optic neuropathy. J Med Genet 26: 739–743.
• Huang WY, Jou MJ, Peng TI (2013). mtDNA T8993G mutationinduced F1F0-ATP synthase defect augments mitochondrial dysfunction associated with hypoxia/reoxygenation: the protective role of melatonin. PLoS One 8: e81546.
• Iommarini L, Maresca A, Caporali L, Valentino ML, Liguori R, Giordano C, Carelli V (2012). Revisiting the issue of mitochondrial DNA content in optic mitochondriopathies. Neurology 79: 1517–1519.
• Janssen AJ, Smeitink JA, van den Heuvel LP (2003). Some practical aspects of providing a diagnostic service for respiratory chain defects. Ann Clin Biochem 40: 3–8.
• Jeppesen TD, Schwartz M, Olsen DB, Wibrand F, Krag T, Duno M, Hauerslev S, Vissing J (2006). Aerobic training is safe and improves exercise capacity in patients with mitochondrial myopathy. Brain 129: 3402–3412.
• Johnson MA, Turnbull DM, Dick DJ, Sherratt HS (1983). A partial deficiency of cytochrome c oxidase in chronic progressive external ophthalmoplegia. J Neurol Sci 60: 31–53.
• Jou MJ, Peng TI, Yu PZ, Jou SB, Reiter RJ, Chen JY, Wu HY, Chen CC, Hsu LF (2007). Melatonin protects against common deletion of mitochondrial DNA-augmented mitochondrial oxidative stress and apoptosis. J Pineal Res 43: 389–403.
• Kanabus M, Heales SJ, Rahman S (2014). Development of pharmacological strategies for mitochondrial disorders. Br J Pharmacol 171: 1798–1817.
• Kaufman BA, Durisic N, Mativetsky JM, Costantino S, Hancock MA, Grutter P, Shoubridge EA (2007). The mitochondrial transcription factor TFAM coordinates the assembly of multiple DNA molecules into nucleoid-like structures. Mol Biol Cell 18: 3225–3236.
• Kaufmann KB, Buning H, Galy A, Schambach A, Grez M (2013). Gene therapy on the move. EMBO Mol Med 5: 1642–1661.
• Kaufmann P, Engelstad K, Wei Y, Jhung S, Sano MC, Shungu DC, Millar WS, Hong X, Gooch CL, Mao X et al. (2006). Dichloroacetate causes toxic neuropathy in MELAS: a randomized, controlled clinical trial. Neurology 66: 324–330. Kerr DS (2013). Review of clinical trials for mitochondrial disorders: 1997-2012. Neurotherapeutics 10: 307–319.
• Khan NA, Govindaraj P, Meena AK, Thangaraj K (2015). Mitochondrial disorders: challenges in diagnosis & treatment. Indian J Med Res 141: 13–26.
• Kirino Y, Yasukawa T, Ohta S, Akira S, Ishihara K, Watanabe K, Suzuki T (2004). Codon-specific translational defect caused by a wobble modification deficiency in mutant tRNA from a human mitochondrial disease. P Natl Acad Sci USA 101: 15070–15075.
• Koga Y, Ishibashi M, Ueki I, Yatsuga S, Fukiyama R, Akita Y, Matsuishi T (2002). Effects of L-arginine on the acute phase of strokes in three patients with MELAS. Neurology 58: 827–828. Korhonen JA, Pham XH, Pellegrini M, Falkenberg M (2004). Reconstitution of a minimal mtDNA replisome in vitro. EMBO J 23: 2423–2429.
• Kraytsberg Y, Kudryavtseva E, McKee AC, Geula C, Kowall NW, Khrapko K (2006). Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons. Nat Genet 38: 518–520.
• Krishnan KJ, Reeve AK, Samuels DC, Chinnery PF, Blackwood JK, Taylor RW, Wanrooij S, Spelbrink JN, Lightowlers RN, Turnbull DM (2008). What causes mitochondrial DNA deletions in human cells? Nat Genet 40: 275–279.
• Larsson NG, Holme E (1992). Multiple short direct repeats associated with single mtDNA deletions. Biochim Biophys Acta 1139: 311–314.
• Li J, Zhou K, Meng X, Wu Q, Li S, Liu Y, Wang J (2008). Increased ROS generation and SOD activity in heteroplasmic tissues of transmitochondrial mice with A3243G mitochondrial DNA mutation. Genet Mol Res 7: 1054–1062.
• Libri V, Brown AP, Gambarota G, Haddad J, Shields GS, Dawes H, Pinato DJ, Hoffman E, Elliot PJ, Vlasuk GP et al. (2012). A pilot randomized, placebo controlled, double blind phase I trial of the novel SIRT1 activator SRT2104 in elderly volunteers. PLoS One 7: e51395.
• Lieber DS, Calvo SE, Shanahan K, Slate NG, Liu S, Hershman SG, Gold NB, Chapman BA, Thorburn DR, Berry GT et al. (2013). Targeted exome sequencing of suspected mitochondrial disorders. Neurology 80: 1762–1770.
• Liu CS, Cheng WL, Lee CF, Ma YS, Lin CY, Huang CC, Wei YH (2006). Alteration in the copy number of mitochondrial DNA in leukocytes of patients with mitochondrial encephalomyopathies. Acta Neurol Scand 113: 334–341.
• Lombes A, Aure K, Bellanne-Chantelot C, Gilleron M, Jardel C (2014). Unsolved issues related to human mitochondrial diseases. Biochimie 100: 171–176.
• Longley MJ, Nguyen D, Kunkel TA, Copeland WC (2001). The fidelity of human DNA polymerase gamma with and without exonucleolytic proofreading and the p55 accessory subunit. J Biol Chem 276: 38555–38562.
• Mandel H, Szargel R, Labay V, Elpeleg O, Saada A, Shalata A, Anbinder Y, Berkowitz D, Hartman C, Barak M et al. (2001). The deoxyguanosine kinase gene is mutated in individuals with depleted hepatocerebral mitochondrial DNA. Nat Genet 29: 337–341.
• Marchington DR, Scott Brown MS, Lamb VK, van Golde RJ, Kremer JA, Tuerlings JH, Mariman EC, Balen AH, Poulton J (2002). No evidence for paternal mtDNA transmission to offspring or extra-embryonic tissues after ICSI. Mol Hum Reprod 8: 1046–1049.
• Mariotti C, Tiranti V, Carrara F, Dallapiccola B, DiDonato S, Zeviani M (1994). Defective respiratory capacity and mitochondrial protein synthesis in transformant cybrids harboring the tRNA(Leu(UUR)) mutation associated with maternally inherited myopathy and cardiomyopathy. J Clin Invest 93: 1102–1107.
• Marriage BJ, Clandinin MT, Macdonald IM, Glerum DM (2004). Cofactor treatment improves ATP synthetic capacity in patients with oxidative phosphorylation disorders. Mol Genet Metab 81: 263–272.
• McFarland R, Chinnery PF, Blakely EL, Schaefer AM, Morris AA, Foster SM, Tuppen HA, Ramesh V, Dorman PJ, Turnbull DM et al. (2007). Homoplasmy, heteroplasmy, and mitochondrial dystonia. Neurology 69: 911–916.
• McFarland R, Clark KM, Morris AA, Taylor RW, Macphail S, Lightowlers RN, Turnbull DM (2002). Multiple neonatal deaths due to a homoplasmic mitochondrial DNA mutation. Nat Genet 30: 145–146.
• McFarland R, Schaefer AM, Gardner JL, Lynn S, Hayes CM, Barron MJ, Walker M, Chinnery PF, Taylor RW, Turnbull DM (2004). Familial myopathy: new insights into the T14709C mitochondrial tRNA mutation. Ann Neurol 55: 478–484.
• McInerny SC, Brown AL, Smith DW (2009). Region-specific changes in mitochondrial D-loop in aged rat CNS. Mech Ageing Dev 130: 343–349.
• Menezes MJ, Riley LG, Christodoulou J (2014). Mitochondrial respiratory chain disorders in childhood: insights into diagnosis and management in the new era of genomic medicine. Biochim Biophys Acta 1840: 1368–1379.
• Minczuk M, Papworth MA, Kolasinska P, Murphy MP, Klug A (2006). Sequence-specific modification of mitochondrial DNA using a chimeric zinc finger methylase. P Natl Acad Sci USA 103: 19689–19694.
• Minczuk M, Papworth MA, Miller JC, Murphy MP, Klug A (2008). Development of a single-chain, quasi-dimeric zinc-finger nuclease for the selective degradation of mutated human mitochondrial DNA. Nucleic Acids Res 36: 3926–3938.
• Moraes CT, Bacman SR, Williams SL (2014). Manipulating mitochondrial genomes in the clinic: playing by different rules. Trends Cell Biol 24: 209–211.
• Moraes CT, DiMauro S, Zeviani M, Lombes A, Shanske S, Miranda AF, Nakase H, Bonilla E, Werneck LC, Servidei S et al. (1989). Mitochondrial DNA deletions in progressive external ophthalmoplegia and Kearns-Sayre syndrome. N Engl J Med 320: 1293–1299.
• Moraes CT, Shanske S, Tritschler HJ, Aprille JR, Andreetta F, Bonilla E, Schon EA, DiMauro S (1991). mtDNA depletion with variable tissue expression: a novel genetic abnormality in mitochondrial diseases. Am J Hum Genet 48: 492–501.
• Naviaux RK (2004). Developing a systematic approach to the diagnosis and classification of mitochondrial disease. Mitochondrion 4: 351–361.
• Naviaux RK, Nguyen KV (2004). POLG mutations associated with Alpers’ syndrome and mitochondrial DNA depletion. Ann Neurol 55: 706–712.
• Nesbitt V, Pitceathly RD, Turnbull DM, Taylor RW, Sweeney MG, Mudanohwo EE, Rahman S, Hanna MG, McFarland R (2013). The UK MRC Mitochondrial Disease Patient Cohort Study: clinical phenotypes associated with the m.3243A>G mutation- -implications for diagnosis and management. J Neurol Neurosurg Psychiatry 84: 936–938.
• Newmeyer DD, Ferguson-Miller S (2003). Mitochondria: releasing power for life and unleashing the machineries of death. Cell 112: 481–490.
• Nishino I, Spinazzola A, Hirano M (1999). Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder. Science 283: 689–692.
• Ohtake A, Murayama K, Mori M, Harashima H, Yamazaki T, Tamaru S, Yamashita Y, Kishita Y, Nakachi Y, Kohda M et al. (2014). Diagnosis and molecular basis of mitochondrial respiratory chain disorders: exome sequencing for disease gene identification. Biochim Biophys Acta 1840: 1355–1359.
• Oliveira MT, Garesse R, Kaguni LS (2010). Animal models of mitochondrial DNA transactions in disease and ageing. Exp Gerontol 45: 489–502.
• Olivo PD, Van de Walle MJ, Laipis PJ, Hauswirth WW (1983). Nucleotide sequence evidence for rapid genotypic shifts in the bovine mitochondrial DNA D-loop. Nature 306: 400–402.
• Palladino MJ (2010). Modeling mitochondrial encephalomyopathy in Drosophila. Neurobiol Dis 40: 40–45.
• Pan Y, Nishida Y, Wang M, Verdin E (2012). Metabolic regulation, mitochondria and the life-prolonging effect of rapamycin: a mini-review. Gerontology 58: 524–530.
• Pandi-Perumal SR, BaHammam AS, Brown GM, Spence DW, Bharti VK, Kaur C, Hardeland R, Cardinali DP (2013). Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes. Neurotox Res 23: 267–300.
• Parikh S, Saneto R, Falk MJ, Anselm I, Cohen BH, Haas R, Medicine Society TM (2009). A modern approach to the treatment of mitochondrial disease. Curr Treat Options Neurol 11: 414–430.
• Peng TI, Hsiao CW, Reiter RJ, Tanaka M, Lai YK, Jou MJ (2012). mtDNA T8993G mutation-induced mitochondrial complex V inhibition augments cardiolipin-dependent alterations in mitochondrial dynamics during oxidative, Ca2+, and lipid insults in NARP cybrids: a potential therapeutic target for melatonin. J Pineal Res 52: 93–106.
• Picard M, Zhang J, Hancock S, Derbeneva O, Golhar R, Golik P, O’Hearn S, Levy S, Potluri P, Lvova M et al. (2014). Progressive increase in mtDNA 3243A>G heteroplasmy causes abrupt transcriptional reprogramming. P Natl Acad Sci USA 111: E4033–4042.
• Poulton J, Kennedy S, Oakeshott P, Wells D (2009). Preventing transmission of maternally inherited mitochondrial DNA diseases. BMJ 338: b94.
• Pozzan T, Magalhaes P, Rizzuto R (2000). The comeback of mitochondria to calcium signalling. Cell Calcium 28: 279–283. Quinzii CM, Hirano M (2010). Coenzyme Q and mitochondrial disease. Dev Disabil Res Rev 16: 183–188.
• Rahman S, Poulton J (2009). Diagnosis of mitochondrial DNA depletion syndromes. Arch Dis Child 94: 3–5.
• Rahman S, Poulton J, Marchington D, Suomalainen A (2001). Decrease of 3243 A-->G mtDNA mutation from blood in MELAS syndrome: a longitudinal study. Am J Hum Genet 68: 238–240.
• Reddy P, Ocampo A, Suzuki K, Luo J, Bacman SR, Williams SL, Sugawara A, Okamura D, Tsunekawa Y, Wu J et al. (2015). Selective elimination of mitochondrial mutations in the germline by genome editing. Cell 161: 459–469.
• Rotig A, Cormier V, Blanche S, Bonnefont JP, Ledeist F, Romero N, Schmitz J, Rustin P, Fischer A, Saudubray JM et al. (1990). Pearson’s marrow-pancreas syndrome. A multisystem mitochondrial disorder in infancy. J Clin Invest 86: 1601–1608.
• Rovio AT, Marchington DR, Donat S, Schuppe HC, Abel J, Fritsche E, Elliott DJ, Laippala P, Ahola AL, McNay D et al. (2001). Mutations at the mitochondrial DNA polymerase (POLG) locus associated with male infertility. Nat Genet 29: 261–262.
• Saada A, Shaag A, Mandel H, Nevo Y, Eriksson S, Elpeleg O (2001). Mutant mitochondrial thymidine kinase in mitochondrial DNA depletion myopathy. Nat Genet 29: 342–344.
• Santorelli FM, Mak SC, El-Schahawi M, Casali C, Shanske S, Baram TZ, Madrid RE, DiMauro S (1996a). Maternally inherited cardiomyopathy and hearing loss associated with a novel mutation in the mitochondrial tRNA(Lys) gene (G8363A). Am J Hum Genet 58: 933–939.
• Santorelli FM, Mak SC, Vazquez-Memije ME, Shanske S, Kranz-Eble P, Jain KD, Bluestone DL, De Vivo DC, DiMauro S (1996b). Clinical heterogeneity associated with the mitochondrial DNA T8993C point mutation. Pediatr Res 39: 914–917.
• Santra S, Gilkerson RW, Davidson M, Schon EA (2004). Ketogenic treatment reduces deleted mitochondrial DNAs in cultured human cells. Ann Neurol 56: 662–669.
• Sarzi E, Bourdon A, Chretien D, Zarhrate M, Corcos J, Slama A, Cormier-Daire V, de Lonlay P, Munnich A, Rotig A (2007). Mitochondrial DNA depletion is a prevalent cause of multiple respiratory chain deficiency in childhood. J Pediatr 150: 531– 534.e6.
• Schaefer AM, McFarland R, Blakely EL, He L, Whittaker RG, Taylor RW, Chinnery PF, Turnbull DM (2008). Prevalence of mitochondrial DNA disease in adults. Ann Neurol 63: 35–39.
• Schon EA, Rizzuto R, Moraes CT, Nakase H, Zeviani M, DiMauro S (1989). A direct repeat is a hotspot for large-scale deletion of human mitochondrial DNA. Science 244: 346–349.
• Schwartz M, Vissing J (2002). Paternal inheritance of mitochondrial DNA. N Engl J Med 347: 576–580.
• Schwartz M, Vissing J (2004). No evidence for paternal inheritance of mtDNA in patients with sporadic mtDNA mutations. J Neurol Sci 218: 99–101.
• Sgarbi G, Casalena GA, Baracca A, Lenaz G, DiMauro S, Solaini G (2009). Human NARP mitochondrial mutation metabolism corrected with alpha-ketoglutarate/aspartate: a potential new therapy. Arch Neurol 66: 951–957.
• Shadel GS, Clayton DA (1997). Mitochondrial DNA maintenance in vertebrates. Annu Rev Biochem 66: 409–435.
• Shoffner JM, Lott MT, Lezza AM, Seibel P, Ballinger SW, Wallace DC (1990). Myoclonic epilepsy and ragged-red fiber disease (MERRF) is associated with a mitochondrial DNA tRNALys mutation. Cell 61: 931–937.
• Shokolenko I, Venediktova N, Bochkareva A, Wilson GL, Alexeyev MF (2009). Oxidative stress induces degradation of mitochondrial DNA. Nucleic Acids Res 37: 2539–2548.
• Short KR, Bigelow ML, Kahl J, Singh R, Coenen-Schimke J, Raghavakaimal S, Nair KS (2005). Decline in skeletal muscle mitochondrial function with aging in humans. P Natl Acad Sci USA 102: 5618–5623.
• Sitarz KS, Almind GJ, Horvath R, Czermin B, Gronskov K, Pyle A, Taylor RW, Larsen M, Chinnery PF, Yu-Wai-Man P (2012). OPA1 mutations induce mtDNA proliferation in leukocytes of patients with dominant optic atrophy. Neurology 79: 1515– 1517.
• Spelbrink JN, Li FY, Tiranti V, Nikali K, Yuan QP, Tariq M, Wanrooij S, Garrido N, Comi G, Morandi L et al. (2001). Human mitochondrial DNA deletions associated with mutations in the gene encoding Twinkle, a phage T7 gene 4-like protein localized in mitochondria. Nat Genet 28: 223–231.
• Suomalainen A, Elo JM, Pietilainen KH, Hakonen AH, Sevastianova K, Korpela M, Isohanni P, Marjavaara SK, Tyni T, Kiuru-Enari S et al. (2011). FGF-21 as a biomarker for muscle-manifesting mitochondrial respiratory chain deficiencies: a diagnostic study. Lancet Neurol 10: 806–818.
• Suomalainen A, Isohanni P (2010). Mitochondrial DNA depletion syndromes--many genes, common mechanisms. Neuromuscul Disord 20: 429–437.
• Szklarczyk R, Nooteboom M, Osiewacz HD (2014). Control of mitochondrial integrity in ageing and disease. Philos T R Soc Lond B 369: 20130439.
• Tanaka M, Borgeld HJ, Zhang J, Muramatsu S, Gong JS, Yoneda M, Maruyama W, Naoi M, Ibi T, Sahashi K et al. (2002). Gene therapy for mitochondrial disease by delivering restriction endonuclease SmaI into mitochondria. J Biomed Sci 9: 534– 541.
• Tatuch Y, Christodoulou J, Feigenbaum A, Clarke JT, Wherret J, Smith C, Rudd N, Petrova-Benedict R, Robinson BH (1992). Heteroplasmic mtDNA mutation (T----G) at 8993 can cause Leigh disease when the percentage of abnormal mtDNA is high. Am J Hum Genet 50: 852–858.
• Taylor RW, Chinnery PF, Turnbull DM, Lightowlers RN (1997). Selective inhibition of mutant human mitochondrial DNA replication in vitro by peptide nucleic acids. Nat Genet 15: 212–215.
• Taylor RW, Giordano C, Davidson MM, d’Amati G, Bain H, Hayes CM, Leonard H, Barron MJ, Casali C, Santorelli FM et al. (2003a). A homoplasmic mitochondrial transfer ribonucleic acid mutation as a cause of maternally inherited hypertrophic cardiomyopathy. J Am Coll Cardiol 41: 1786–1796.
• Taylor RW, McDonnell MT, Blakely EL, Chinnery PF, Taylor GA, Howell N, Zeviani M, Briem E, Carrara F, Turnbull DM (2003b). Genotypes from patients indicate no paternal mitochondrial DNA contribution. Ann Neurol 54: 521–524.
• Taylor RW, Turnbull DM (2005). Mitochondrial DNA mutations in human disease. Nat Rev Genet 6: 389–402. Temperley RJ, Seneca SH, Tonska K, Bartnik E, Bindoff LA, Lightowlers RN, Chrzanowska-Lightowlers ZM (2003).
• Investigation of a pathogenic mtDNA microdeletion reveals a translation-dependent deadenylation decay pathway in human mitochondria. Hum Mol Genet 12: 2341–2348.
• Tuppen HA, Blakely EL, Turnbull DM, Taylor RW (2010). Mitochondrial DNA mutations and human disease. Biochim Biophys Acta 1797: 113–128.
• Upholt WB, Dawid IB (1977). Mapping of mitochondrial DNA of individual sheep and goats: rapid evolution in the D loop region. Cell 11: 571–583.
• Vafai SB, Mootha VK (2012). Mitochondrial disorders as windows into an ancient organelle. Nature 491: 374–383.
• Van Goethem G, Luoma P, Rantamaki M, Al Memar A, Kaakkola S, Hackman P, Krahe R, Lofgren A, Martin JJ, De Jonghe P et al. (2004). POLG mutations in neurodegenerative disorders with ataxia but no muscle involvement. Neurology 63: 1251–1257.
• Vasta V, Merritt JL 2nd, Saneto RP, Hahn SH (2012). Next-generation sequencing for mitochondrial diseases: a wide diagnostic spectrum. Pediatr Int 54: 585–601.
• Vilkki J, Savontaus ML, Nikoskelainen EK (1990). Segregation of mitochondrial genomes in a heteroplasmic lineage with Leber hereditary optic neuroretinopathy. Am J Hum Genet 47: 95– 100.
• Villa-Cuesta E, Holmbeck MA, Rand DM (2014). Rapamycin increases mitochondrial efficiency by mtDNA-dependent reprogramming of mitochondrial metabolism in Drosophila. J Cell Sci 127: 2282–2290.
• Viscomi C, Burlina AB, Dweikat I, Savoiardo M, Lamperti C, Hildebrandt T, Tiranti V, Zeviani M (2010). Combined treatment with oral metronidazole and N-acetylcysteine is effective in ethylmalonic encephalopathy. Nat Med 16: 869– 871.
• Wallace DC, Singh G, Lott MT, Hodge JA, Schurr TG, Lezza AM, Elsas LJ 2nd, Nikoskelainen EK (1988). Mitochondrial DNA mutation associated with Leber’s hereditary optic neuropathy. Science 242: 1427–1430.
• Wenz T, Diaz F, Hernandez D, Moraes CT (2009). Endurance exercise is protective for mice with mitochondrial myopathy. J Appl Physiol (1985) 106: 1712–1719.
• Wong A, Cavelier L, Collins-Schramm HE, Seldin MF, McGrogan M, Savontaus ML, Cortopassi GA (2002). Differentiation-specific effects of LHON mutations introduced into neuronal NT2 cells. Hum Mol Genet 11: 431–438.
• Wong LJ (2007). Diagnostic challenges of mitochondrial DNA disorders. Mitochondrion 7: 45–52.
• Yang J, Zhu Y, Tong Y, Chen L, Liu L, Zhang Z, Wang X, Huang D, Qiu W, Zhuang S et al. (2009). Confirmation of the mitochondrial ND1 gene mutation G3635A as a primary LHON mutation. Biochem Biophys Res Commun 386: 50–54.
• Yasukawa T, Suzuki T, Ishii N, Ueda T, Ohta S, Watanabe K (2000). Defect in modification at the anticodon wobble nucleotide of mitochondrial tRNALys with the MERRF encephalomyopathy pathogenic mutation. FEBS Lett 467: 175–178.
• Zeviani M, Moraes CT, DiMauro S, Nakase H, Bonilla E, Schon EA, Rowland LP (1988). Deletions of mitochondrial DNA in Kearns-Sayre syndrome. Neurology 38: 1339–1346.
• Zhu Z, Yao J, Johns T, Fu K, De Bie I, Macmillan C, Cuthbert AP, Newbold RF, Wang J, Chevrette M et al. (1998). SURF1, encoding a factor involved in the biogenesis of cytochrome c oxidase, is mutated in Leigh syndrome. Nat Genet 20: 337